RESEARCH MEETING
May ~~20~~ 19, 1992

In preparation for our meeting on May ~~20~~ 19, 1992, it will be helpful to have the information regarding Philip Morris primary research that I have been able to gather over the past several months. If anything is omitted, please let me know as soon as possible. I would not like anything to show up later which will affect our funding decisions for 1993.

Our purpose, on May ~~20~~ 19, will be to discuss the merits of all currently funded research and research proposals in order to assist in determining what research we should fund in 1993. Foremost in our consideration should be the scientific quality of the research. Second, will the research move us toward an answer to the question of what, if any, role cigarette smoking may play in certain diseases? Third, will the research help provide answers to the questions of what factors play a role in some of the diseases associated with cigarette smoking? Finally, what other criteria should play a role in our recommendations? For example, is it important to support research in certain countries, because we need to have a "research presence" in certain markets?

I will start by listing the research we are currently sponsoring (1992), the current funding amounts, and the Philip Morris organization currently responsible for the funding. I will also include, to the extent I am aware, future funding obligations. This will be followed by research proposals for future funding.

2028355892

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

(18)	P. Guisnet Covington & Burling	France
(19)	P. Hellstroem Covington & Burling	Sweden
(20)	M. P. Iurato Covington & Burling	Italy
(21)	K.S. Larsson Covington & Burling	Sweden
(22)	P. Lee Covington & Burling	U.K.
(23)	G. B. Leslie Covington & Burling	U.K.
(24)	F. Lunau Covington & Burling	U.K.
(25)	T. Malmfors Covington & Burling	Sweden
(26)	L. Manzo Covington & Burling	Italy
(27)	B. Martin Covington & Burling	U.K.
(28)	B. Mikaelsson Covington & Burling	France
(29)	A. Navarro Covington & Burling	France
(30)	G. Neurath Covington & Burling	Germany
(31)	O. Nilsen Covington & Burling	Norway
(32)	R. Perry Covington & Burling	U.K.

2028355900

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

G. Anthony Papconstantinou - Greece. Study of the correlation between the presence of Glutathione S-Transferace μ and the development and histological type of lung cancer in smokers. See attached Exhibit E. $60,500+. See Exhibit G.

H. Hans Altmann. See Exhibit H.

I hope that our discussions will lead to some consensus on what research Philip Morris should fund in 1993 and, if necessary, beyond.

2028355903

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

3. Rylander
- -Role of Airborne Glucan and Endotoxin in Indoor Air Quality -- CIAR Project.
- Lung Cancer: Role of Factors other than Smoking -- Emphasis on Diet. (Case-control epidemiological study funded by Swedish Medical Board. Also collaboration with Linda Koo, Hong Kong).
- $60,000/year unrestricted research grant;
- $90,000/year consultancy.

B. Case Western University: Drs. Friedland and Whitehouse. The Effects of Cigarette Smoking on the Development of Alzheimer's Disease: Epidemiological, Clinical and Neurobiological Studies.

Funding Commitments:

1992	- $1,240,000
1993	- 2,100,000
1994	- 700,000

C. Meyer Friedman Institute, San Francisco. Epidemiological study of 3,000 persons with Type A behavior. One-half will receive five years of Type A counseling designed to modify their behavior, while the other half will receive no counseling. The subjects will be monitored for ten years, to monitor the development of heart disease and cancer. The issue to be addressed is: what, if any, role does Type A behavior play in the development of heart disease and cancer in previously healthy individuals.

Funding Commitment:

November 1, 1992	- $ 697,000

Funding Request:

November 1993-November 1998	- $6,479,577

1998

2028355898

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

(3)	Peter Atteslander Shook, Hardy & Bacon	Switzerland
(4)	Karl Baettig (nicotine)	Switzerland
(5)	D. Bienfait Covington & Burling	France
(6)	C. Bieva Shook, Hardy & Bacon	Belgium
(7)	Jean Boddewgn Covington & Burling	Belgium
(8)	A. Cerioli (science communication ETS) Covington & Burling	Italy
(9)	G. Crepat (Member of Aria) Covington & Burling	France
(10)	J. Descotes (ETS) Covington & Burling	U.S.A.
(11)	S. Dinardi Covington & Burling	U.S.A.
(12)	J. Faccini Covington & Burling	France
(13)	A. Fave Covington & Burling	France
(14)	J.E.R. Frijters (part of Arise Group)	Netherlands
(15)	R. Fritsch Covington & Burling	France
(16)	G. Gori Covington & Burling	U.S.A.
(17)	J. Gerrod P. Martin	U.K.

2028355899

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

V. **Australia (ATRF).**

Grants	1992 Funding (Aust. $)
P.G. Board	49,733
D.G. Byrne	76,690
J.E. Kellow	44,235
Continuing Grants (previous years)	147,000
Scholarships	
M.C. Bates	17,800
G. Grigoriadis	14,180
Continuing Scholarships (previous years)	14,180
Program Grants	187,000
Total	550,818
PM Total 35%	192,786

Attached, as Exhibit A, is a memo to me from Phil Francis, dated February 14, 1992, listing some of the research projects currently being funded by the ATRF.

VI. **Inbifo.**

A.	Yearly budget:	approximately $14,000,000
	PM-USA share	$11,681,000
	FTR	approximately $2,319,000
	CRC yearly budget:	$5,100,000 (already included in the approximately $14,000,000).
B.	Breakdown of Activities:	see attached Exhibit B.

2028355896

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

Symann	Oncology - post-doctorate fellowship; cell transformation through solid tumors; Brussels	55,000
Vincze	DNA adducts - adduct levels are not related to cancer; Institute of Public Health, Budapest	60,000

All of the above are one year commitments.

I understand that there is funding through Covington & Burling, but that it is considered ETS research.

Kings College (Prof. Gorrod)	Tobacco Alkaloids	37,900
Kings College (Prof. Gorrod)	Nicotine Conjugates	55,600
Weetman (IAI)	Decision Making	50,000
Nilsen (Trondheim U.)	Nicotine Measurements	$252,400

II. Netherlands (Stitchting).

Researcher	Title and Comments	1992 Funding (Dfl)
Anthonie von Leeuwenhoekhuis	Basic cancer research; The Dutch Cancer Institute	27,500
CIVO/TNO Institute	Research re influence of cigarette smoke on bronchial tubes and influence of Vitamin A	55,000

2028355894

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

Snow	Genotoxic factors regarding the arising of head and neck cancer; Amsterdam Free University ENT Clinic	66,000
Van Bekkum	Radiobiologic research; Radiobiologic Institute	-
	Total	148,500
	20%	$16,500

III. **Switzerland (AFSC).**

Researcher	Title and Comments	1992 Budget (CHF)
Bättig	Behavior and benefits of smoking;	100,000
Brunner	Hypertension;	100,000
Cerutti	Molecular biology;	100,000
Haab	Respiratory physiology;	100,000
	Total	400,000
	PM Total	200,000

IV. **Belgium (Fetetab).**

Researcher	Title and Comments	1992 Budget (CHF)
Malherbe	~~Benefits of smoking - behavior study; (paid for by PM-Belgium Marketing);~~ cancelled	9,000

2028355895

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

(33)	A. Poma Shook, Hardy & Bacon	Italy
(34)	M. Reasor Covington & Burling	U.S.A.
(35)	A. Rico Covington & Burling	France
(36)	G. Robertson Covington & Burling	U.S.A.
(37)	F.J.C. Roe Covington & Burling	U.K.
(38)	B. Schneider	Germany
(39)	S. Schwartz Covington & Burling	U.S.A.
(40)	A. Sherlock	U.K.
(41)	P. Skrabanek Covington & Burling	Ireland
(42)	J. P. Tassin (nicotine)	France
(43)	D. Thorburn Covington & Burling	Sweden
(44)	G. Tymen Covington & Burling	France
(45)	A. Viala Covington & Burling	France
(46)	T. Voss	Denmark
(47)	J. Wahren (nicotine and Arise)	Sweden
(48)	D. M. Warburton (nicotine)	U.K.
(49)	D. F. Weetman Covington & Burling	U.K.

2028355901

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

C. Research Goals:

23.2%	1.	Critically evaluate credible claims regarding the biological activity of mainstream smoke.
24.8%	2.	Identify the differences between the biological activity of fresh sidestream and ETS-like smoke.
11.9%	3.	Identify and investigate pertinent single smoke components and smoke fractions, in order to decrease the biological activity of smoke.
7.1%	4.	Investigate the suitability of smoke components (nicotine) for the biomonitoring of smoke uptake.
10.6%	5.	Evaluate the impact of product modifications on biological activity, and recommend desirable changes.
11.1%	6.	Generate and investigate alternative aerosols.
.3%	7.	Ensure product quality by monitoring residues and contaminants.
10.8%	8.	Enhance the consulting expertise in order to provide reliable information and technical support.

VII. Philip Morris-USA.

A. Consultants:

1.	Abood	- Nicotine Pharmacology; - $85,000/year research grant; - $5,000/year consultancy.
2.	Guzelian	- Adverse Effects of Toxic Substances in the Environment; - $100,000/year to October 1993; - $1,000/day consultancy.

2028355897

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

(50) L. Werkoe
Covington & Burling Sweden

(50) A. Westlin
Covington & Burling Sweden

XI. **Research Applications.**

A. Meyer Friedman Institute: see VII. C.

B. Duke University - Dr. Red Williams. See Exhibit D. Research into the effects of stress and increased cholesterol levels on the development and spread of tumors. This is animal and cell research, as contrasted with the epidemiological research of Dr. Friedman. Duke is requesting:

1992 - $380,000

1993 - 380,000.

C. Medical College of Virginia - Linden Eves. Jim Charles or Richard Carchman will explain.

D. Johns Hopkins University School of Medicine: see attached Exhibit E.

E. Peter Lee. Statistical analysis of accuracy of disease diagnosis. Peter Martin will explain. £5,000. See Exhibit F.

F. D. Warburton. For partial sponsorship of a conference on "Quality of Life Issues," which will have multi-industry support. The conference is planned for late 1992. Peter Martin will explain. £20,000.

2028355902

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000

I. **Primary Issue Grants formerly with FTR-S&T, now with Philip Morris-USA (Jim Charles).**

Researcher	Title and Comments	1992 Funding (CHF)
Caboche	Neurophysiology (thesis); this is only for 1992; University of Paris	20,400
Tassin	Neuroreceptors - nicotine receptors in the brain and tobacco's effect on increasing learning and concentration; College of France	FF 350000. 89,100
Dusser	Airway enzymes - what happens to enzymes after exposure to smoke; Faculty of Medicine-Paris	300000. 57,300
Molimard	Smoking behavior; Faculty of Medicine-Paris	250000. 63,600
Micheletti	Parkinson's disease - study in rats; Strasbourg	300000. 57,300
Hirt	Papilloma virus - possible involvement of viruses in some cancers; Swiss Institute for Experimental Cancer Research	95,000
Syrjaenen	Papilloma virus - looking at lung cancer, laryngeal cancer and HPV; University of Kuopio, Finland	131,800
Schneider	Biometrics - risk assessment; using computer models to show competitive risks; University of Hanover	98,700

2028355893

Source: https://www.industrydocuments.ucsf.edu/docs/fryj0000